How Many Meridian Bioscience, Inc. (NASDAQ:VIVO)’s Analysts Are Bullish?

April 23, 2018 - By Richard Conner

Meridian Bioscience, Inc. (NASDAQ:VIVO) LogoInvestors sentiment decreased to 1.2 in Q4 2017. Its down 0.17, from 1.37 in 2017Q3. It worsened, as 21 investors sold Meridian Bioscience, Inc. shares while 44 reduced holdings. 31 funds opened positions while 47 raised stakes. 36.52 million shares or 0.72% more from 36.26 million shares in 2017Q3 were reported.
Clark Estates reported 227,000 shares. Blackrock reported 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO). 175,000 were reported by Gamco Investors Et Al. Arizona State Retirement Sys has invested 0.01% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Legal And General Group Inc Pcl reported 87,493 shares. California State Teachers Retirement Systems holds 0% or 65,661 shares in its portfolio. Massachusetts-based Arrowstreet Partnership has invested 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO). First Manhattan accumulated 7,000 shares. Prudential Inc has 376,224 shares for 0.01% of their portfolio. Natl Bank Of Montreal Can accumulated 1,737 shares. Tudor Investment Et Al has invested 0.02% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Teacher Retirement Sys Of Texas holds 0% or 14,456 shares in its portfolio. Mondrian Invest Prtn owns 177,739 shares for 0.06% of their portfolio. Ohio-based Park Natl Oh has invested 0.01% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Verity Asset Mngmt stated it has 10,267 shares.

Since February 7, 2018, it had 2 insider buys, and 0 selling transactions for $28,784 activity. The insider Rice John McCune Jr. bought $14,750.

Meridian Bioscience, Inc. (NASDAQ:VIVO) Ratings Coverage

Among 3 analysts covering Meridian Bioscience Inc (NASDAQ:VIVO), 0 have Buy rating, 1 Sell and 2 Hold. Therefore 0 are positive. Meridian Bioscience Inc has $16.0 highest and $11.0 lowest target. $14.33’s average target is -1.51% below currents $14.55 stock price. Meridian Bioscience Inc had 3 analyst reports since January 25, 2018 according to SRatingsIntel. Canaccord Genuity maintained the stock with “Hold” rating in Thursday, January 25 report. The firm earned “Hold” rating on Thursday, January 25 by Robert W. Baird. Piper Jaffray maintained Meridian Bioscience, Inc. (NASDAQ:VIVO) rating on Thursday, January 25. Piper Jaffray has “Sell” rating and $11.0 target. Below is a list of Meridian Bioscience, Inc. (NASDAQ:VIVO) latest ratings and price target changes.

25/01/2018 Broker: Piper Jaffray Rating: Sell New Target: $11.0 Maintain
25/01/2018 Broker: Canaccord Genuity Rating: Hold New Target: $16.0 Maintain
25/01/2018 Broker: Robert W. Baird Rating: Hold New Target: $16.0 Maintain

The stock decreased 1.36% or $0.2 during the last trading session, reaching $14.55. About 143,447 shares traded. Meridian Bioscience, Inc. (NASDAQ:VIVO) has risen 7.87% since April 23, 2017 and is uptrending. It has underperformed by 3.68% the S&P500.

Meridian Bioscience, Inc., a life science company, develops, makes, distributes, and sells diagnostic test kits primarily for various gastrointestinal, viral, respiratory, and parasitic infectious diseases worldwide. The company has market cap of $615.58 million. The firm operates through Diagnostics and Life Science divisions. It has a 28.53 P/E ratio. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the illumigene brand; rapid immunoassays, a single-use immunoassays that can be used in point-of-care settings under the TRU, ImmunoCard, and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the Premier brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand.

Meridian Bioscience, Inc. (NASDAQ:VIVO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.